Stay updated with breaking news from Astrazeneca Media. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The MANDARA trial results, published in NEJM, show benralizumab's noninferiority to mepolizumab in eosinophilic granulomatosis with polyangiitis, with potential for oral glucocorticoid discontinuation.
Published: Dec 14, 2020 By Mark Terry AstraZeneca CEO Pascal Soriot pictured above. Photo courtesy of AstraZeneca. Alexion Pharmaceuticals for $39 billion. Alexion shareholders will get $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADS), with each ADS worth half of an ordinary AstraZeneca share. The deal otherwise comes to about $175 per share. The deal has been approved by both companies’ boards and is expected to close in the third quarter of 2021. AstraZeneca’s focus has been on oncology, cardiovascular, renal and metabolism and respiratory diseases. It has al...